Bicycle Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Bicycle Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 0.7% bzw. 50.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -47.2% betragen.
Wichtige Informationen
5.4%
Wachstumsrate der Gewinne
13.8%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 28.3% |
| Wachstumsrate der Einnahmen | 52.2% |
| Zukünftige Eigenkapitalrendite | -47.2% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 19 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 63 | -268 | -218 | -159 | 10 |
| 12/31/2025 | 35 | -236 | -208 | -169 | 12 |
| 12/31/2024 | 42 | -179 | -139 | -104 | 12 |
| 6/30/2024 | 40 | -165 | -165 | -164 | N/A |
| 3/31/2024 | 42 | -168 | -86 | -85 | N/A |
| 12/31/2023 | 27 | -181 | -64 | -61 | N/A |
| 9/30/2023 | 25 | -162 | -48 | -44 | N/A |
| 6/30/2023 | 23 | -140 | -55 | -48 | N/A |
| 3/31/2023 | 15 | -124 | -122 | -106 | N/A |
| 12/31/2022 | 14 | -113 | -105 | -86 | N/A |
| 9/30/2022 | 15 | -101 | -85 | -66 | N/A |
| 6/30/2022 | 16 | -87 | -54 | -39 | N/A |
| 3/31/2022 | 14 | -78 | -34 | -27 | N/A |
| 12/31/2021 | 12 | -67 | -17 | -15 | N/A |
| 9/30/2021 | 12 | -66 | -22 | -21 | N/A |
| 6/30/2021 | 11 | -62 | -54 | -53 | N/A |
| 3/31/2021 | 11 | -56 | -54 | -53 | N/A |
| 12/31/2020 | 10 | -51 | -19 | -18 | N/A |
| 9/30/2020 | 12 | -38 | -7 | -6 | N/A |
| 6/30/2020 | 9 | -37 | -8 | -7 | N/A |
| 3/31/2020 | 9 | -35 | -4 | -2 | N/A |
| 12/31/2019 | 14 | -31 | -30 | -29 | N/A |
| 9/30/2019 | 10 | -33 | -34 | -33 | N/A |
| 6/30/2019 | 11 | -31 | -28 | -26 | N/A |
| 3/31/2019 | 11 | -26 | -25 | -24 | N/A |
| 12/31/2018 | 7 | -22 | -27 | -26 | N/A |
| 9/30/2018 | 7 | -21 | -20 | -19 | N/A |
| 12/31/2017 | 2 | -16 | N/A | -1 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BCYC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: BCYC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: BCYC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: BCYCDie Einnahmen des Unternehmens (47.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: BCYCDie Einnahmen des Unternehmens (47.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BCYC wird voraussichtlich in 3 Jahren unrentabel sein.